

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CSPC PHARMACEUTICAL GROUP LIMITED**

### **石藥集團有限公司**

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 1093)**

### **VOLUNTARY ANNOUNCEMENT**

#### **ACCEPTANCE OF NEW DRUG APPLICATION FOR “MITOXANTRONE HYDROCHLORIDE LIPOSOME INJECTION”**

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that, the new drug application for “mitoxantrone hydrochloride liposome injection (10ml: 10mg)” (the “**Product**”) developed by CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd\* (石藥集團中諾藥業(石家莊)有限公司), a subsidiary of the Company, submitted has been accepted by the Center for Drug Evaluation of National Medical Products Administration of the People’s Republic of China. The indication for this application is for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma who have received at least one prior first-line standard therapy.

The Product is the world’s first mitoxantrone liposome preparation developed by the Group with full intellectual property rights, and is a Class 2.2 new drug of improved formulation. This new drug application is mainly based on the results of a single-arm, open, multi-centre phase II study of mitoxantrone hydrochloride liposome injection in relapsed/refractory peripheral T-cell and NK/T-cell lymphoma.

There is currently no similar product available on the worldwide market. The Group will make its utmost effort to expedite the launch of the Product.

By order of the Board  
**CSPC Pharmaceutical Group Limited**  
**Cai Dongchen**  
*Chairman*

Hong Kong, 25 August 2020

*As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi and Mr. CHAK Kin Man as executive directors; Mr. LEE Ka Sze, Carmelo as non-executive director; and Mr. CHAN Siu Keung, Leonard, Mr. WANG Bo, Prof. LO Yuk Lam, Dr. YU Jinming and Mr. CHEN Chuan as independent non-executive directors.*

\* *For identification purpose only*